PT - JOURNAL ARTICLE AU - Turner, Katy AU - Zienkiewicz, Adam AU - Rees, Nicolas Verscheuren Van AU - Christensen, Hannah AU - Hill, Darryl AU - Homer, Martin AU - Hughes, Gwenda AU - Horner, Paddy AU - Looker, Katharine AU - Ong, Jason TI - P646 Agent-based modelling study of antimicrobial resistant <em>neisseria gonorrhoeae</em> transmission AID - 10.1136/sextrans-2019-sti.714 DP - 2019 Jul 01 TA - Sexually Transmitted Infections PG - A285--A285 VI - 95 IP - Suppl 1 4099 - http://sti.bmj.com/content/95/Suppl_1/A285.1.short 4100 - http://sti.bmj.com/content/95/Suppl_1/A285.1.full SO - Sex Transm Infect2019 Jul 01; 95 AB - Background Antimicrobial resistant (AMR) gonorrhoea is a global public health threat. Diagnoses of gonorrhoea have increased in England over the last decade. Guidelines in UK now recommend single dose ceftriaxone, so preserving the efficacy of ceftriaxone is essential. In England, over half of tested isolates remain sensitive to previously recommended drugs, e.g. ciprofloxacin. We evaluate options for improving antibiotic stewardship, through better use of existing surveillance data or new diagnostic tests.Methods We previously developed an agent-based stochastic network model of gonorrhoea transmission, including ciprofloxacin-sensitive and resistant strains for MSM. This has been modified, to add a heterosexual population and a full model including bridging between MSM and heterosexuals. A novel feature is the time-varying network which breaks and reforms connections within a fixed cumulative network to capture behavioural heterogeneity in duration and number of partnerships. We explored different strategies to facilitate individualised treatment selection, including discriminatory POCT, and selecting treatment based on either index case or partner susceptibility.Results Our MSM model suggests, based on 50% resistance to ciprofloxacin at baseline, that using POCT to detect ciprofloxacin-sensitive infections could reduce ceftriaxone doses by 70%. If index case susceptibility information were to be used to determine partner treatment, ceftriaxone use could be reduced by 27%. In the heterosexual model, the prevalence is much lower and could only be maintained through assuming higher transmission probability or duration of infection or via bridging to the higher prevalence MSM group.Conclusion Novel POCT which identify susceptible infections are likely to come to market soon, but are costly. Mathematical models can evaluate the trade-offs between increasing test costs and reduced time to treatment or between delaying treatment to confirm susceptibility and reduce use of ceftriaxone in partners. The flexible model structure will be used in future to implement evolution of resistance and the impact of vaccination.Disclosure No significant relationships.